Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TAM family kinases as therapeutic targets at the interface of cancer and immunity
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 755-779
Closed Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
Jin Zhang, Yue Ma
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116909-116909
Open Access | Times Cited: 7
Downregulation of MerTK in circulating T cells of patients with non-proliferative diabetic retinopathy
Shimiao Bu, Jiang-Yue Ling, Xiao-Jun Wu, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access
AXL: shapers of tumor progression and immunosuppressive microenvironments
Yihui Liu, Lei Xu, Yuanyao Dou, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Copper Chelate Targeting Externalized Phosphatidylserine Inhibits PD-L1 Expression and Enhances Cancer Immunotherapy
Fan Gao, Wei You, Lei Zhang, et al.
Journal of the American Chemical Society (2025)
Closed Access
Current status and future prospects of molecular imaging in targeting the tumor immune microenvironment
Xiang Wang, Wen Shen, Lan Yao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Tetrahedral Framework Nucleic Acid Relieves Sepsis‐Induced Intestinal Injury by Regulating M2 Macrophages
Tingting Tan, Jiajie Li, Wensi Fan, et al.
Cell Proliferation (2025)
Open Access
Exploiting Structural Variability in the Kinase Back-Pocket to Modulate Polypharmacology of Tam Inhibitors
Megan D. Hopkins, Dehui� Zhang, Zhilong Chen, et al.
(2025)
Closed Access
AXL signaling in cancer: from molecular insights to targeted therapies
Monika Yadav, Anuj K. Sharma, Ketki Patne, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Promoting Diabetic Wound Healing through a Hydrogel‐Based Cascade Regulation Strategy of Fibroblast‐Macrophage
Nuo Jin, Zilin Wang, Xi Tang, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 16
Open Access | Times Cited: 4
AXL receptor as an emerging molecular target in colorectal cancer
Lucía De Rosa, Rossella Di Stasi, Virginia Fusco, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 6, pp. 104005-104005
Closed Access | Times Cited: 3
Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance
Yumin Fu, Xinyu Guo, Linmao Sun, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 3
The TAM Subfamily of Receptor Tyrosine Kinases: The Early Years
Anne L. Prieto, Cary Lai
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3369-3369
Open Access | Times Cited: 2
Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors
Deyu Kong, Qiang Tian, Zhilong Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5866-5882
Closed Access | Times Cited: 2
AXL inhibition suppresses early allograft monocyte-to-macrophage differentiation and prolongs allograft survival
Collin Z. Jordan, Matthew Tunbridge, Irma Husain, et al.
JCI Insight (2024) Vol. 9, Iss. 5
Open Access | Times Cited: 1
In the Eyes of the Beholder—New Mertk Knockout Mouse and Re-Evaluation of Phagocytosis versus Anti-Inflammatory Functions of MERTK
Sourav Ghosh, Silvia C. Finnemann, Douglas Vollrath, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5299-5299
Open Access | Times Cited: 1
MERTK Inhibition as a Targeted Novel Cancer Therapy
K.M. Tanim, Alisha Holtzhausen, Aashis Thapa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7660-7660
Open Access | Times Cited: 1
Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis
Nabil F. Saba, Ritu Chaudhary, Kedar Kirtane, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 20, pp. 4601-4608
Closed Access | Times Cited: 1
Anti-inflammatory effects of MerTK by inducing M2 macrophage polarization via PI3K/Akt/GSK-3β pathway in gout
Fangfang Chen, Yixuan Li, Li Zhao, et al.
International Immunopharmacology (2024) Vol. 142, pp. 112942-112942
Closed Access | Times Cited: 1
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor
Yi‐Yun Yu, Miyeon Jang, Julie M. Miyashiro, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 19, pp. 17000-17032
Closed Access | Times Cited: 1
Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer
Anne Knisely, Emily Hinchcliff, Elisabeth Gardiner, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109801-109801
Open Access
Patient-derived induced pluripotent stem cells with a MERTK mutation exhibit cell junction abnormalities and aberrant cellular differentiation potential
Hang Zhang, Ling-Zi Wu, Zhenyu Liu, et al.
World Journal of Stem Cells (2024) Vol. 16, Iss. 5, pp. 512-524
Open Access
NT157 as an Anticancer Drug Candidate That Targets Kinase- and Phosphatase-Mediated Signaling
Keli Lima, João Agostinho Machado‐Neto
Kinases and Phosphatases (2024) Vol. 2, Iss. 2, pp. 179-189
Open Access
Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment
Mu‐Chun Li, You-Liang Lai, Po-Hsien Kuo, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 10906-10927
Open Access
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer
Anwaar Saeed, Josep Tabernero, Aparna R. Parikh, et al.
Future Oncology (2024) Vol. 20, Iss. 24, pp. 1733-1743
Closed Access
On-target site enriching fluorescent bioprobe for imaging of receptor tyrosine kinase in tumor
Meng Gao, Jiqiu Yin, XianChao Jia, et al.
Chinese Chemical Letters (2024), pp. 110297-110297
Closed Access
Page 1 - Next Page

Scroll to top